Bundibugyo virus glycoprotein seroreactivity following recombinant vesicular stomatitis virus-Zaire Ebola virus glycoprotein vaccination in outbreak-affected populations of the Democratic Republic of the Congo: a longitudinal cohort study

Halbrook M, Merritt S, Hoff NA, Mukadi P, Kompany JP, Musene K, Beya M, Kalengi H, Tambu M, Kelly JD, Ball AH, To A, MacGill T, Orr R, Myers T, Woods CW, Nicholson BP, Wong TA, Hensley LE, Kindrachuk J, Lehrer AT, Mbala-Kingebeni P, Rimoin AW. Bundibugyo virus glycoprotein seroreactivity following recombinant vesicular stomatitis virus-Zaire Ebola virus glycoprotein vaccination in outbreak-affected populations of the Democratic Republic of the Congo: a longitudinal cohort study. Lancet. 2026 Aug 25:S0140-6736(26)01608-9. doi: 10.1016/S0140-6736(26)01608-9. Epub ahead of print. PMID: 42641631.


Related Posts